HC Wainwright Issues Optimistic Forecast for AQST Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – HC Wainwright raised their Q1 2026 earnings estimates for shares of Aquestive Therapeutics in a report issued on Monday, March 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.12) per share for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.51) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.12) EPS and Q4 2027 earnings at ($0.11) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million.

Several other equities analysts have also commented on the company. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $8.80.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.20 on Wednesday. The firm has a market cap of $512.57 million, a P/E ratio of -5.38 and a beta of 1.61. The firm’s 50-day simple moving average is $4.13 and its 200-day simple moving average is $5.22. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after buying an additional 1,333,627 shares in the last quarter. Federated Hermes Inc. increased its stake in Aquestive Therapeutics by 159.4% during the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after purchasing an additional 1,249,044 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 6,233.4% during the fourth quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock valued at $7,569,000 after buying an additional 1,153,175 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $5,918,000. Finally, Wells Fargo & Company MN grew its position in Aquestive Therapeutics by 804.6% during the fourth quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after buying an additional 1,057,145 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright updated its model, raising several near‑term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses in some quarters vs prior forecasts — a sign analysts see improving operating performance ahead. MarketBeat AQST
• Positive Sentiment: A Seeking Alpha piece reiterates a Buy view and an $8 fair‑value for AQST, arguing that Anaphylm’s FDA issues are addressable (labeling/packaging) and that approval odds and commercial adoption assumptions support substantial upside if resolved. Aquestive Therapeutics: With Some Hiccups…
• Neutral Sentiment: Aquestive granted an inducement equity award to its Chief Medical Officer — standard retention comp that is generally neutral for near‑term valuation but supports management continuity during regulatory work. Inducement Award
• Neutral Sentiment: Published short‑interest figures in recent reports look anomalous (zeros/NaN), so don’t read much into the published days‑to‑cover metrics until verified by exchange data. (No actionable link provided.)
• Negative Sentiment: Multiple securities‑class action complaints and law‑firm solicitations have been filed/announced (Rosen, Faruqi & Faruqi, Bernstein Liebhard, The Gross Law Firm, Robbins LLP), alleging damages tied to disclosures in a prior class period — these legal risks can increase volatility, raise potential liability/defense costs, and weigh on sentiment. Representative notices: Rosen Law Firm Faruqi & Faruqi The Gross Law Firm

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.